Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Galderma Pioneers NDA Path Into OTC Acne Treatment Market

Executive Summary

FDA on July 8 announces approval for Galderma Laboratories to market Differin Gel 0.1% (adapalene) as an OTC, once-daily topical for treatment of acne by consumers 12 years old and up.

Advertisement

Related Content

Differin Gel Enters Changed Marketplace Since Last OTC Acne Drug Approval
Keeping Track: Xiidra, New Repatha Regimen Approved; Abuse-Deterrent Opioid Gets Negative, But Timely, Response
Nestle's Prospects To Lead OTC Acne Market Gel With Differin Approval
PDUFA Clock Ticks For FDA Decision On First OTC Acne Ingredient NDA

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS118723

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel